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Background: Exacerbations are a key outcome in clinical research, providing patient-relevant
information about symptomatic control, health state and disease progression. Generally
considered as an episode of (sub)acute deterioration of respiratory symptoms, a precise, clin-
ically useful definition is needed for use in clinical trials.
Aim and methods: Focussing on moderate exacerbations, this opinion piece reviews landmark
trials and current guidelines to provide a practical definition of a moderate exacerbation. Spe-
cifically, we adapt the ATS/ERS consensus statement of terminology Reddel et al. (2009) [1]
which provides a conceptual (or ‘theoretical’) definition for moderate exacerbations, to an
operational (or ‘practical’) criterion suitable for use in clinical research.
Results: The proposed definition for a moderate exacerbation requires 1 of the following
criteria combined with a change in treatment: a) nocturnal awakening(s) due to asthma
requiring SABA for 2 consecutive nights or an increase of 0.75 from baseline in daily symptom
scores on 2 consecutive days; b) increase from baseline in occasions of SABA use on 2 consec-
utive days (minimum increase: 4 puffs/day); c) 20% decrease in PEF from baseline on at least1 494 7460.
d.uni-rostock.de, jc.h.virchow@sunrise.ch (J.C. Virchow).
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548 J.C. Virchow et al.2 consecutive mornings/evenings or 20% decrease in FEV1 from baseline and/or d) visit to the
emergency room/trial site for asthma treatment not requiring systemic corticosteroids.
Conclusion: A clinically and patient-relevant, operational definition of moderate exacerba-
tions is needed. The proposed definition has been endorsed by the EMA Scientific Advice Work-
ing Party in 2011and needs to be trialled in forthcoming clinical studies.
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Exacerbations are increasingly recognised as a cornerstone
for evaluating the management of asthma and gauging the
success of interventions to reduce future risk. The Global
Initiative for Asthma (GINA) guidelines recommend regular
monitoring, and state that moderate exacerbations should
be treated accordingly before they become severe [2]. The
ostensible value of moderate exacerbations is as an inter-
mediary stage at which physician intervention can mitigate
progression to severe exacerbation. However, neither GINA,
consensus guidelines from the World Health Organisation,
the National Asthma Education and Prevention Task Force
nor the NHLBI/NIAID Asthma Outcomes Workshop publica-
tion on Exacerbations [3]) provide guidance on how to
stratify severity or how to define a moderate exacerbation.
Currently, moderate exacerbations are largely defined
subjectively according to the patients’ experience and the
physician-led changes in clinical management; in contrast,
clinical trials with patient-relevant endpoints require consis-
tent, prospective, clearly defined endpoints to compare study
interventions. Without such clinically relevant data, the evi-
dence on which best practice is based becomes considerably
weakened, creating a circular problem. Based on the defini-
tions of previous studies, this position paper attempts to pro-
vide a definition for moderate exacerbations that can be
trialled, reviewing keywork andguidelines toprovidecontext.
Exacerbations as an endpoint in clinical trials:
reviewing the evidence
Critical clinical studies have used a variety of definitions,
examples of which are summarised in Table 1 [4e18], it is
noteworthy that no core, landmark studies have used asingle, coherent definition of exacerbation. The diverse
terminology invalidates comparison of endpoints between
studies and complicates pooling of data for meta-analyses
[19]; it also undermines perspectives in the aetiology, risk
factors and associations for exacerbations, which are crit-
ical for developing strategies of symptom control.
In the current literature, exacerbations are sometimes
described by change in medication (most frequently, an
increase in inhaled steroid use), but across clinical research
as a whole, the utility of medication type or dose in
reducing the risk of progression to severe exacerbation may
itself be the subject of the investigation. For this reason,
exacerbations should be defined by other clinical criteria as
well. Other key criteria include lung function (PEF or FEV1
e which have been questioned regarding their usefulness as
patient relevant outcomes), though notably thresholds
vary, and indices of symptom worsening such as nocturnal
awakening due to asthma.
A few general points can also be made about the level of
stratification from the studies summarised below (Table 1).
The emphasis in clinical research has, historically, focussed
on severe exacerbations, which can be more clearly defined
around the criterion of hospitalisation. Less mention is
made of mild exacerbations, possibly because these are
difficult to distinguish from intra- and inter-patient vari-
ability of baseline symptoms. Moderate exacerbations,
however, are also not clearly defined in milestone studies;
this may in part be because the interest in them as an
endpoint is relatively recent. However, the advantages of a
definition for moderate exacerbation go beyond clarity of
trial reporting to improve outcomes for patients; inter-
vention at the moderate stage could prevent patients from
developing a severe exacerbation, which may require more
intense treatment including hospitalisations. Accordingly,
any intervention which reduces moderate exacerbations
Table 1 Defining asthma exacerbations in previous clinical trials. The studies listed in Table 1 used different criteria for
exacerbations and most were published before the ATS/ERS Task Force recommendations in 2009. Since then, harmonisation in
definitions of severe exacerbations has been attempted in clinical trials, but a uniform definition is still lacking.
Reference Design, patients (n) and
intervention
Primary outcome
measurement
Definition of
exacerbation
Incidence of
exacerbation
Sears MR et al., 1990 [4]. 24-week double-blind,
placebo-controlled,
randomised cross-over
study
Patients with stable
asthma (n Z 89)
Fenoterol versus placebo
Control defined by daily
morning and evening
PEF, symptoms diaries,
use of additional
bronchodilator
medication and
requirement for
prednisone
Exacerbations
mentioned as a symptom
in the study, but not
defined
57/64 subjects
showed a clear
difference in degree
of control of asthma
between the
fenoterol and placebo
periods
Evans DJ et al., 1997 [5]. 12-week randomised,
controlled, double-blind,
parallel group study
Patients with asthma
(n Z 62) treated with
either:
1. Inhaled budesonide
400 mg (low
dose) þ theophylline
250 or 375 mg
(depending on body
weight) or
2. Inhaled budesonide
800 mg (high dose)
Lung function: peak
expiratory flow,
FEV1, and forced vital
capacity (FVC) and the
reversibility of
abnormalities in FEV1.
Patient diaries recording
twice daily
entries of three PEF
measurements, albuterol
usage, and
severity of symptoms
Exacerbations were
defined as:
Mild: two consecutive
days with any of the
following: decrease in
morning PEF by more
than 20% of base line,
nocturnal symptoms, or
the need for more than
four puffs of albuterol
or
Severe: decrease in
morning PEF by more
than 30% on two
consecutive days.
Mild exacerbations:
range 0e11; median 3
in high dose
budesonide range 0
e13;
median 2 in the group
given low-dose
budesonide plus
theophylline.
Severe
exacerbations: Three
exacerbations during
the study (two in the
given high-dose
budesonide group and
one in the low dose
group).
The FACET study
Pauwels RA et al.,
1997 [6].
1 yr randomised, double-
blind, controlled trial
with 4 treatment arms
Patients with asthma >6
months, treated with
inhaled
glucocorticosteroid (>3
months)
1. Budesonide
100 mg þ placebo
2. Budesonide
100 mg þ 12 mg
formoterol
3. Budesonide
400 mg þ placebo
4. Budesonide
400 mg þ 12 mg
formoterol
The rates of severe and/
or mild exacerbations
per patient per year.
A severe exacerbation
was defined as one
requiring treatment with
oral gluco-
corticosteroids, as
judged by the
investigator, or a
decrease in the peak
expiratory flow as
measured in the morning
to more than 30% below
the baseline value on
two consecutive days.
73% of severe
exacerbations were
identified clinically by
the investigators. The
baseline peak expiratory
flow was defined as the
mean peak expiratory
flow in the morning
during the last 10 days of
the run-in period.
Days with mild
exacerbations were
defined as days when one
of the following
occurred: a peak
expiratory flow in the
The number of severe
exacerbations for
treatment groups 1e4
was: 153, 125, 90 and
57 respectively, and
for mild
exacerbations: 5953,
3980, 4289, 2241.
(continued on next page)
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Table 1 (continued )
Reference Design, patients (n) and
intervention
Primary outcome
measurement
Definition of
exacerbation
Incidence of
exacerbation
morning that was more
than 20% below the base-
line value; the use of
more than three
additional inhalations of
terbutaline per 24 h as
compared with the base-
line period; or
awakening at night due
to asthma. Single,
isolated days of mild
exacerbations were not
counted. The base-line
value was the mean
value for the variable
during the last 10 days of
the run-in period.
Tattersfield AE et al.,
1999 [7].
Subset analysis of the FACET study (above) explored characteristics and risk factors for the severe
exacerbations observed (n Z 425): a gradual fall in PEF over several days, followed by more rapid
changes over 2e3 days; parallel use of rescue-medication and symptom increase; higher incidence in
female patients
The START study
Pauwels RA et al.,
2003 [8].
O’Byrne PM et al.,
2009 [9].
and
O’Byrne PM et al.,
2010 [10].
3-yr, randomised,
double-blind, placebo-
controlled trial
Patients with mild
persistent asthma <2
years (n Z 7165)
Placebo versus 400 mg, or
200 mg inhaled
budesonide
Time to first serious
asthma-related event
(SARE)
Part of a composite
definition, SARE. This
was defined as events
requiring hospitalisation
or emergency treatment
due to worsening of
asthma, or death due to
asthma. Emergency
treatment was defined as
treatment of acute
airway obstruction with
systemic
glucocorticosteroids and
nebulised or parenteral
bronchodilators
administered in a health-
care setting.
198 of 3568 patients
on placebo and 117 of
3597 on budesonide
had at least one
severe asthma
exacerbation; hazard
ratio 0.56 (95% CI 0.45
e0.71, p < 0.0001).
The STAY study
O’Byrne PM et al.,
2005 [11].
and
O’Byrne PM et al.,
2007 [12].
1 yr, randomised,
controlled, double-blind,
parallel-group study
Patients with asthma
treated with ICS and a
history of exacerbations
(n Z 2760)
Patients treated with:
1. Terbutaline
0.4 mg þ budesonide/
formoterol (BD), 80/
4.5 mg
2. Terbutaline
0.4 mg þ budesonide
320 mg (BD)
3. Budesonide/for-
moterol (BD), 80/
Time to first severe
exacerbation
Severe asthma
exacerbations were
defined as a
deterioration in asthma
resulting in
hospitalisation/
emergency room
treatment, oral steroid
treatment (or an
increase in ICS [via a
separate inhaler] and/or
other additional
treatment for children
aged 4e11 years), or
morning peak expiratory
flow of 70% or less of
baseline on 2
consecutive days.
Mild exacerbations were
Events per patient
year for groups 1, 2
and 3 respectively:
0.68, 0.68 and 0.36
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Table 1 (continued )
Reference Design, patients (n) and
intervention
Primary outcome
measurement
Definition of
exacerbation
Incidence of
exacerbation
4.5 mg with Budeso-
nide/formoterol as
needed
defined as 2 consecutive
days with either a
morning PEF of 80% or
less of baseline, as-
needed use [of] two or
more inhalation[s] per
day above baseline, or
awakenings caused by
asthma.
Rabe KF et al., 2006 [13]. 1 yr, double-blind,
parallel-group study with
three treatment arms
Patients using inhaled
corticosteroids
(n Z 3394)
Budesonide-formoterol
(maintenance) plus as
needed medication:
1. Terbutaline (0.4 mg)
2. Formoterol (4.5 mg)
3. Budesonide-for-
moterol combination
at 160 mg þ 4.5 mg
Time to first severe
exacerbation
A severe exacerbation
was defined as
deterioration in asthma
resulting in emergency
treatment or
hospitalisation or the
need for oral steroids for
3 days or more (as
judged by the
investigator).
The rates of severe
exacerbations were
37, 29, and 19 per 100
patients/year for
treatment groups 1, 2
and 3 respectively
Kuna P et al., 2007 [14]. 6-month, randomised
double-blind controlled
trial
Patients  12 years with
asthma for  6 months
(n Z 4399) using ICS  3
months
Budesonide/formoterol
(160/4.5 mg, OD plus
additional inhalations as
needed, [SMART] vs
salmeterol/fluticasone
(25/125 mg BID inhalation
with terbutaline as
needed) vs budesonide/
formeterol (320/9 mg OD
inhalation with
terbutaline as needed)
The primary variable was
the time to first severe
exacerbation
Severe exacerbations
were defined as
deterioration in asthma
resulting in
hospitalisation or
emergency room (ER)
treatment, or the need
for oral steroids for  3
days (as judged by the
investigator).
A mild exacerbation day
was defined as a day with
any one of the following:
morning PEF 20% below
baseline, daily as-
needed medication use
2 inhalations above
baseline or a night with
an asthma-related
awakening, calculated
from diary-card data. A
mild exacerbation was
defined as two
consecutive mild
exacerbation days
satisfying the same
criterion.
There was a 33%
reduction in hazard
ratio for a first severe
exacerbation with
SMART compared with
salmeterol/
fluticasone, and a 26%
reduction compared
with budesonide/
formeterol and
terbutaline
Maneechotsesuwan K.
2007 [15].
12-week randomised
double-blind controlled
trial
Patients with moderate
stable asthma (n Z 24)
The onset of
exacerbation following
withdrawal of
corticosteroid
An exacerbation was
defined as at least one of
three criteria: (1) a drop
in morning peak flow
20% below baseline
The fast withdrawal
of inhaled
corticosteroids led to
an increase in sputum
neutrophils and IL-8
(continued on next page)
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Table 1 (continued )
Reference Design, patients (n) and
intervention
Primary outcome
measurement
Definition of
exacerbation
Incidence of
exacerbation
Budesonide (400 mg
b.i.d.) or placebo
(mean of the last 7 days
run-in period) on 2
consecutive days; (2)
wakening due to asthma
on 2 consecutive nights,
and requiring rescue
medication; (3) 50%
increase in 24-h rescue
medication use on at
least 2 consecutive days
compared to mean use
during the last 7 days of
the run-in period, which
also exceeded the
equivalent of four puffs
of terbutaline. FEV1 was
then measured within
24 h of the exacerbation.
concentrations.
Following this,
patients experienced
exacerbation of
asthma.
The GOAL study
Bateman ED et al.,
2008 [16].
1 yr, randomised double-
blind controlled trial
Patients with
uncontrolled asthma
(n Z 3421)
Salmeterol/fluticasone
propionate vs fluticasone
propionate
Totally or well-
controlled asthma,
defined as a composite
endpoint; the absence of
an exacerbation was
necessary for control
Defined as a
deterioration in asthma
requiring treatment with
an oral corticosteroid or
an emergency
department visit, and/or
hospitalisation
In patients achieving
well-controlled or
totally controlled
asthma, at least well-
controlled asthma
was maintained for a
median of almost 3
and
6 months, and for
more than 85% and
95% of weeks of
follow-up,
respectively.
2009 e ATS/ERS Task
force
recommendations [1]
Nathan RA et al., 2010
[17].
26-week multicentre,
double-blind, double-
dummy, randomized,
placebo-controlled trial
Patients (n Z 781) with
uncontrolled asthma on
medium dose inhaled
corticosteroids
Mometasone furoate/
formoterol (200/10 mg)
versus its
monocomponents versus
placebo, all b.i.d.
The time to first asthma
deterioration and the
bronchodilatory effect of
MF/F versus MF.
An asthma deterioration
was defined as any one
of the three following
events: (1) an
occurrence of any
clinically judged
deterioration that
resulted in emergency
treatment,
hospitalization due to
asthma, or treatment
with additional excluded
asthma medication (i.e.,
systemic
corticosteroids); (2) a
0% decrease from the
average of the two
predose FEV1
measurements taken just
before the first dose of
randomized study
medica-tion; or (3) a
30% decrease from the
The combined drug
group was superior to
its individual
components or
placebo for both of
the primary
endpoints.
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Table 1 (continued )
Reference Design, patients (n) and
intervention
Primary outcome
measurement
Definition of
exacerbation
Incidence of
exacerbation
respective aver-age A.M.
or P.M. PEF baseline
measurements (obtained
over the 7 days
immediately before
receiving the first dose of
randomized study
medication) for at least 2
consecutive days.
Meltzer EO et al., 2012
[18].
26-week, multicentre,
double-blind, placebo-
controlled study
Patients (n Z 746) with
poorly controlled asthma
on low-dose inhaled
corticosteroids
Mometasone furoate/
formoterol (100/10 mg)
versus its
monocomponents versus
placebo, all b.i.d.
Time to first asthma
deterioration and change
in forced expiratory
volume in 1 s (FEV1)
An asthma deterioration
was defined as a
clinically judged
deterioration (i.e.
asthma attack resulting
in emergency treatment,
hospitalisation or
treatment with
additional, excluded
asthma medication (i.e.
systemic
corticosteroids)) or a
meaningful reduction in
lung function (i.e. a
decrease in FEV1 of
>20% from baseline at
any study visit or a
decrease in PEF of >30%
from baseline for 2
days consecutively at
any time during the
treatment period).
The combined drug
group was superior to
its individual
components or
placebo for both of
the primary
endpoints.
Legend: Full reference details of studies are provided in the reference list. Classification of exacerbations is given as direct quotations
from the published texts, for clarity.
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vere exacerbations.
A clear definition of moderate exacerbation:
contributions to future clinical research and
understanding
A combined ATS/ERS Task Force reviewed the Cochrane li-
brary database for publications from 1998 to 2004 (studies
included, n Z 327). Its primary objective was to stan-
dardise terminology used in asthma research to support
data collection methods in future clinical trials, with a
particular focus on definitions of asthma control, severity
and exacerbation [1].
Definitions for each measure took into account the
following: the congruity of information (is the measure
consistent with existing understanding of asthma?); the
extent of a given measure to support treatment aims (for
example, did the measure achieve good control of symp-
toms or a reduced risk to patients?); the characteristics of
the measure relevant to its use in clinical studies (how easyit is to reproduce the measure, assess it and how does it
associate with other measures?) and the feasibility of use
(will use of the measure be limited by measures such as
safety, accessibility and/or cost?). The resulting compre-
hensive review proposed a precise definition for mild,
moderate and severe exacerbations, that has been pub-
lished by the ATS/ERS Task Force (Callout Box 1). The au-
thors concluded that ‘more work is needed to develop
simple feasible criteria for defining exacerbations in clinical
practice’ [1].
Theoretical classifications such as the ATS/ERS defini-
tions are useful but invariably retrospective, as they
depend largely on treatment decisions such as drug use.
This may be sufficient in clinical practice, but for clinical
trials, a more specific, prospective definition is needed to
ensure consistency [19]. In chronic obstructive pulmonary
disease, data suggest that comparing symptom-defined as
opposed to healthcare-defined exacerbation rates results in
clinically relevant differences in incidence levels [20] with
a resultant impact on economic and care burden [21,22].
Furthermore, patients might adjust medication inappro-
priately in response to perceived symptom changes [23].
Callout Box 1. Defining moderate exacerbations: The ATS/ERS consensus statement (direct quotation from Reddel et al.,
2009 [1]).
Moderate asthma exacerbations
1. A moderate asthma exacerbation is an event that, when recognised, should result in a temporary change in treatment,
in an effort to prevent the exacerbation from becoming severe.
2. The definition of a moderate asthma exacerbation should include one or more of the following: deterioration in
symptoms, deterioration in lung function, and increased rescue bronchodilator use. These features should last for 2 days
or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalisation. ER visits for asthma
(e.g. for routine sick care), not requiring systematic corticosteroids, may be classified as moderate exacerbations.
3. The magnitude of change in these outcomes will differ depending on the population studied and each individual pa-
tient’s baseline variation.
554 J.C. Virchow et al.Translating clinical definitions to an
operational setting: a new definition
Therefore, the ATS/ERS definition of a moderate asthma
exacerbation should be translated into an operational
format suitable for a clinical trial environment (Callout Box
2). This proposed definition of a moderate asthma exacer-
bation suitable for use in clinical trials was endorsed by the
European Medicines Agency Scientific Advice Working Party
in February 2011. In constructing this definition, not only a
change in medication, but also the clinical observations
that precede a change in treatment, providing clear
thresholds for diagnosis across four key criteria were taken
into account.
Although the validity of these criteria compared with
other criteria still need to be tested prospectively, the in-
dividual criteria in Box 2 have been used before with vari-
ations in other studies. It is noteworthy that small
differences in criteria can make a large difference in
exacerbation rates [1]. To move the field forward, meth-
odology will have to be developed to evaluate the utility of
different criteria in various combinations.
The hypothesis that this adapted ATS/ERS definition of a
moderate exacerbation can be used in clinical research is
currently under investigation in a phase III controlled trial
of allergy immunotherapy (MITRA trial, ALK, Horsholm,Callout Box 2. Defining moderate exacerbations: The MITRA s
[24]).
A moderate exacerbation is defined as ‡1 of criteria a)ed) f
a) Nocturnal awakening(s) due to asthma requiring SABA for 2
daily symptom score on 2 consecutive days
b) Increase from baseline in occasions of SABA use on 2 conse
c) 20% decrease in PEF same from baseline on at least 2 cons
baseline
d) Visit to the emergency room/trial site for asthma treatmenDenmark) with the primary endpoint being a reduction in
the risk for an asthma exacerbation. Moderate and severe
exacerbations were defined as described by the ATS/ERS
Task Force [1]. Studies exploring exacerbations in asthma
have largely focused on severe exacerbations, but it might
be more relevant to capture information about moderate
exacerbations, thus exploring the potential for earlier in-
terventions to mitigate disease progression and maintain
and/or improve control and prevent future severe
exacerbations.
Such future trials will be needed to review the success of
the proposed definition. In order to achieve more wide-
spread acceptance, the definition will need to be used far
more widely; for example, trialling for different drug
classes. It will also be necessary to explore how the mod-
erate exacerbation endpoint works across key subgroups,
for example: pregnant women; those with particularly se-
vere asthma; the elderly, the paediatric population; ado-
lescents and those with complications in asthma. Refining
this definition to support use in especially vulnerable pa-
tient groups may include strategies for gathering informa-
tion from patients who have difficulty in expressing their
symptoms and/or where there may be difficulty in col-
lecting classic metric data. Future research and wider
participation should reveal these answers, and may also
provide further elucidation of operational definitions fortudy protocol (direct quotation from Virchow et al., 2013
ulfilled and leading to a change in treatment:
consecutive nights or increase of 0.75 from baseline in
cutive days (minimum increase: 4 puffs/day)
ecutive mornings/evenings or 20% decrease in FEV1 from
t not requiring systemic corticosteroids
Defining moderate asthma exacerbations 555mild and severe exacerbations. It remains unclear to what
extent the results of this analysis will be generalisable to
other populations such as those with poor pulmonary
function, different age and at greater risk for exacerba-
tions, but using such a definition would be a starting point
for further comparative analysis.
Conclusion
Exacerbations are increasingly likely to be a focal endpoint
in clinical trials as they represent a patient- and healthcare
system-relevant endpoint. Accordingly, there is a clear
need for a standard definition. This will enable comparison
of treatments and procedures, meta-analysis to strengthen
the evidence-base, and will improve trial quality. Further-
more, many physicians may welcome a practical,
observation-led definition of moderate exacerbation that
enables them to identify patients at risk of developing se-
vere exacerbations, and to develop strategies to prevent
this.
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